Sanders M. Inhalation therapy: an historical review. Prim Care Respir J. 2007;16:71–81.
Article
PubMed
PubMed Central
Google Scholar
Chrystyn H. Closer to an “ideal inhaler” with the Easyhaler: an innovative dry powder inhaler. Clin Drug Investig. 2006;26:175–83.
CAS
Article
PubMed
Google Scholar
UN Environment (UNEP). Handbook for the montreal protocol on substances that deplete the ozone layer, 10th edn. 2016. https://observatoriop10.cepal.org/sites/default/files/documents/treaties/mp-handbook-2016-english.pdf. Accessed 27 Aug 2019.
Crompton GK. Dry powder inhalers: advantages and limitations. J Aerosol Med. 1991;4:151–6.
CAS
Article
PubMed
Google Scholar
Lavorini F, Corrigan CJ, Barnes PJ, Dekhuijzen PRN, Levy ML, Pedersen S, et al. Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med. 2011;105:1099–103.
CAS
Article
PubMed
Google Scholar
Sellers WFS. Asthma pressurised metered dose inhaler performance: propellant effect studies in delivery systems. Allergy, Asthma Clin Immunol. 2017;13:30.
Article
CAS
Google Scholar
UN Environment (UNEP). Handbook for the montreal protocol on substances that deplete the ozone layer, 12th edn. 2018. https://ozone.unep.org/sites/default/files/MP_handbook-english-2018.pdf. Accessed 22 July 2019.
Laube BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308–417.
CAS
Article
PubMed
Google Scholar
Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004;1:67–86.
CAS
Article
PubMed
Google Scholar
Kinnunen H, Hebbink G, Peters H, Shur J, Price R. An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations. AAPS PharmSciTech. 2014;15:898–909.
CAS
Article
PubMed
PubMed Central
Google Scholar
Ho R, Muresan AS, Hebbink GA, Heng JYY. Influence of fines on the surface energy heterogeneity of lactose for pulmonary drug delivery. Int J Pharm. 2010;388:88–94.
CAS
Article
PubMed
Google Scholar
Zeng XM, Martin GP, Tee SK, Ghoush AA, Marriott C. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int J Pharm. 1999;182:133–44.
CAS
Article
PubMed
Google Scholar
Adi H, Larson I, Chiou H, Young P, Traini D, Stewart P. Role of Agglomeration in the Dispersion of Salmeterol Xinafoate from Mixtures for Inhalation with Differing Drug to Fine Lactose Ratios. J Pharm Sci. 2008;97:3140–52.
CAS
Article
PubMed
Google Scholar
Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50:1209–27.
PubMed
Google Scholar
Weers J, Clark A. The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers. Pharm Res. United States. 2017;34:507–28.
CAS
Google Scholar
Azouz W, Chrystyn H. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Prim Care Respir J. 2012;21:208–13.
Article
PubMed
Google Scholar
Krüger P, Ehrlein B, Zier M, Greguletz R. Inspiratory flow resistance of marketed dry powder inhalers (DPI). Eur Respir J [Internet]. 2014;44:4635. http://erj.ersjournals.com/content/44/Suppl_58/4635.abstract. Accessed 22 July 2019.
Malmberg LP, Everard ML, Haikarainen J, Lähelmä S. Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler®. J Aerosol Med Pulm Drug Deliv. 2014;27:329–40.
CAS
Article
PubMed
PubMed Central
Google Scholar
Delvadia R, Hindle M, Longest PW, Byron PR. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv. 2013;26:138–44.
CAS
Article
PubMed
Google Scholar
Buttini F, Brambilla G, Copelli D, Sisti V, Balducci AG, Bettini R, et al. Effect of flow rate on in vitro aerodynamic performance of NEXThaler® in comparison with diskus® and Turbohaler® dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2016;29:167–78.
CAS
Article
PubMed
PubMed Central
Google Scholar
Pohlmann G, Hohlfeld JM, Haidl P, Pankalla J, Cloes RM. Assessment of the power required for optimal use of current inhalation devices. J Aerosol Med Pulm Drug Deliv [Internet]. 2018;31:339–46. https://doi.org/10.1089/jamp.2017.1376.
Article
Google Scholar
Ghosh S, Ohar JA, Drummond MB. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: implications for Dry Powder Inhalers. J Aerosol Med Pulm Drug Deliv. 2017;30:381–7.
Article
PubMed
PubMed Central
Google Scholar
Voss A, Finlay WH. Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm. 2002;248:39–50
CAS
Article
PubMed
Google Scholar
Mäkelä M, Chrystyn H, Lavorini F, Canonica GW. Back to Basics in Asthma and COPD: optimising the Patient Journey. Eur Med J Respir. 2018;6:47–54.
Google Scholar
Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers–implications for in vitro testing. J Aerosol Med. 1993;6:99–110.
CAS
Article
PubMed
Google Scholar
Palander A, Mattila T, Karhu M, Muttonen E. In vitro Comparison of Three Salbutamol-Containing Multidose Dry Powder Inhalers. Clin Drug Investig. 2000;20:25–33.
CAS
Article
Google Scholar
Jõgi R, Lähelmä S, Vahteristo M, Happonen A, Haikarainen J. In vitro flow rate dependency of delivered dose and fine particle dose of salmeterol/fluticasone propionate easyhaler and seretide diskus with patient flow rates collected in a randomized controlled trial. J Aerosol Med Pulm Drug Deliv. 2018;31:jamp.2018.1463.
Google Scholar
Haidl P, Heindl S, Siemon K, Bernacka M, Cloes RM. Inhalation device requirements for patients’ inhalation maneuvers. Respir Med. 2016;118:65–75.
Article
PubMed
Google Scholar
Azouz W, Chetcuti P, Hosker HSR, Saralaya D, Stephenson J, Chrystyn H. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv. 2015;28:35–42.
Article
PubMed
Google Scholar
Malmberg LP, Rytilä P, Happonen P, Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010;5:257–62.
Article
PubMed
PubMed Central
Google Scholar
Haikarainen J, Selroos O, Löytänä T, Metsärinne S, Happonen A, Rytilä P. Budesonide/Formoterol Easyhaler®: performance under simulated real-life conditions. Pulm Ther. 2017;3:125–38.
Article
Google Scholar
Abadelah M, Hazim F, Chrystyn H, Bagherisadeghi G, Rahmoune H, Larhrib H. Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in vitro from an Easyhaler® dry powder inhaler. Eur J Pharm Sci. 2017;104:180–7.
CAS
Article
PubMed
Google Scholar
Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–8.
Article
PubMed
Google Scholar
Sandler N, Holländer J, Långström D, Santtila P, Saukkonen A, Torvinen S. Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler). BMJ Open Respir Res. 2016;3(1):e000119.
Article
PubMed
PubMed Central
Google Scholar
Takemura M, Kobayashi M, Kimura K, Mitsui K, Masui H, Koyama M, et al. Repeated instruction on inhalation technique improves adherence to the therapeutic regimen in asthma. J Asthma. 2010;47:202–8.
Article
PubMed
Google Scholar
Takemura M, Mitsui K, Itotani R, Ishitoko M, Suzuki S, Matsumoto M, et al. Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:97–104.
Article
PubMed
PubMed Central
Google Scholar
Price DB, Román-Rodríguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, et al. Inhaler Errors in the CRITIKAL Study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract. 2017;5:1071–81.e9.
Article
PubMed
Google Scholar
Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, Inhaler Error Steering Committee, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013;107:37–46.
CAS
Article
PubMed
Google Scholar
Chrystyn H, van der Palen J, Sharma R, Barnes N, Delafont B, Mahajan A, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim care Respir Med. 2017;27:22.
Article
PubMed
PubMed Central
Google Scholar
Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593–604.
Article
PubMed
Google Scholar
Sanchis J, Gich I, Pedersen S, Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150:394–406.
Article
PubMed
Google Scholar
Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med. 2000;94:767–71.
CAS
Article
PubMed
Google Scholar
Aldridge RE, Hancox RJ, Robin Taylor D, Cowan JO, Winn MC, Frampton CM, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med. 2000;161:1459–64.
CAS
Article
PubMed
Google Scholar
Stanford RH, Shah MB, D’Souza AO, Dhamane AD, Schatz M. Short-acting beta-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109:403–7.
CAS
Article
PubMed
Google Scholar
Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149:604–10.
CAS
Article
PubMed
Google Scholar
Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the- counter reliever use in a cross-sectional population survey. BMJ Open. 2017. https://doi.org/10.1136/bmjopen-2017-016688.
Article
PubMed
PubMed Central
Google Scholar
Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007;62:591–604.
CAS
Article
PubMed
Google Scholar
Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA), 2019 [Internet]. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed 13 Jul 2019.
O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled combined budesonide–formoterol as needed in mild asthma. New Engl J Med. 2018;378(20):1865–76.
Article
PubMed
Google Scholar
Bateman E, Reddel H, O’Byrne P, Barnes P, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378:1877–87.
CAS
Article
PubMed
Google Scholar
Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380:2020–30.
Article
PubMed
Google Scholar
Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim care Respir Med. 2014;24:14009.
Article
PubMed
PubMed Central
Google Scholar
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication adherence and persistence according to different antihypertensive drug classes: a retrospective cohort study of 255,500 patients. Int J Cardiol. 2016;220:668–76.
Article
PubMed
Google Scholar
Haahtela T, Herse F, Karjalainen J, Klaukka T, Linna M, Leskelä R-L, et al. The Finnish experience to save asthma costs by improving care in 1987-2013. J Allergy Clin Immunol. 2017;139(408–414):e2.
Google Scholar
Burki TK. Asthma control: learning from Finland's success. Lancet Respir Med. 2019;7:207–8.
Article
PubMed
Google Scholar
Janson C, Lööf T, Telg G, Stratelis G, Nilsson F. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. NPJ Prim Care Respir Med. 2016;26:16053.
Article
PubMed
PubMed Central
Google Scholar
Sulaiman I, Cushen B, Greene G, Seheult J, Seow D, Rawat F, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195:1333–43.
Article
PubMed
Google Scholar
Papi A, Ryan D, Soriano JB, Chrystyn H, Bjermer L, Rodriguez-Roisin R, et al. Relationship of inhaled corticosteroid adherence to asthma exacerbations in patients with moderate-to-severe asthma. J Allergy Clin Immunol Pract. 2018;6:1989–1998.e3.
Article
PubMed
Google Scholar
Plaza V, Giner J, Calle M, Rytilä P, Campo C, Ribó P, et al. Impact of patient satisfaction with his or her inhaler on adherence and asthma control. Allergy Asthma Proc. 2018;39:437–45.
Article
PubMed
PubMed Central
Google Scholar
Valero A, Ribó P, Maíz L, Barbero E, Calle M, Campo C, et al. Asthma patient satisfaction with different dry powder inhalers. Expert Rev Respir Med. 2019;13:133–8.
CAS
Article
PubMed
Google Scholar
Lötvall J, Mellén A, Arvidsson P, Palmqvist M, Radielovic P, Kottakis J, et al. Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler. Can Respir J. 1999;6:412–6.
Article
PubMed
Google Scholar
Virchow JC, Rodriguez-Roisin R, Papi A, Shah TP, Gopalan G. A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma. BMC Pulm Med. 2016;16:42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zetterström O, Lähelmä S, Keski-Karhu J, Silvasti M, Östling-Kulling E, Ahonen A. Salbutamol via Easyhaler®is at least as effective as salbutamol via Turbuhaler®in the treatment of histamine-induced bronchoconstriction. Respir Med. 2000;94:1097–102.
Article
PubMed
Google Scholar
Chuchalin AG, Kremer H-J, Metzenauer P, O’Keefe E, Hermann R. Clinical equivalence trial on budesonide delivered either by the novolizer® multidose dry powder inhaler or the turbuhaler® in asthmatic patients. Respiration. 2002;69:502–8.
CAS
Article
PubMed
Google Scholar
Statens legemiddelverk. Inhalasjonpulver på byttelisten – vedtak gyldig. 2018.